-
公开(公告)号：EP1154988A1
公开(公告)日：2001-11-21
申请号：EP00916832.9
申请日：2000-02-14
发明人： BAENTELI, Rolf , BAUER, Wilfried , COTTENS, Sylvain , EHRHARDT, Claus , HOMMEL, Ulrich , KALLEN, Jörg , MEINGASSNER, Josef, Gottfried , NUNINGER, François , WEITZ-SCHMIDT, Gabriele
IPC分类号： C07C235/26 , C07C237/18 , C07C235/30 , C07C237/20 , C07D211/76 , C07D265/24 , C07D401/06 , A61K31/4402 , A61K31/45 , A61K31/4545 , A61K31/535 , A61P9/10 , A61P3/06 , A61P29/00 , A61P37/00
CPC分类号： C07C271/12 , C07C235/26 , C07C235/30 , C07C237/18 , C07C2602/28 , C07D211/76 , C07D265/10
摘要： Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.
摘要翻译： 其中内酯环被改性的美维诺林衍生物具有令人感兴趣的药物性质，特别是在预防或治疗由LFA-1 / ICAM-1相互作用介导的病症或疾病方面。
-
公开(公告)号：EP0824350A1
公开(公告)日：1998-02-25
申请号：EP96919769.0
申请日：1996-05-10
CPC分类号： A61K31/41 , A61K31/495 , A61K31/135 , A61K2300/00
摘要： Use of a combination of the squalene epoxidase inhibitor terbinafine and an azole 14-alpha-methyldemethylase inhibitor (fluconazole or itraconazole) in mycotic infections caused by azole-resistant fungal strains, and corresponding pharmaceutical compositions, process and method.
-
公开(公告)号：EP1439838A1
公开(公告)日：2004-07-28
申请号：EP02782975.3
申请日：2002-10-22
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/436 , A61K31/133 , A61K31/135
CPC分类号： A61K31/133 , A61K31/135 , A61K31/436 , A61K2300/00
摘要： A pharmaceutical compound comprising a compound of formula I and a pharmaceutically acceptable 2-amino-1,3-propanediol beside one or more pharmaceutically acceptable excipient(s).
-
公开(公告)号：EP1220852A1
公开(公告)日：2002-07-10
申请号：EP00969490.2
申请日：2000-10-11
申请人： Novartis AG
发明人： ALBERT, Rainer , EHRHARDT, Claus , HOMMEL, Ulrich , KALLEN, Jörg , MEINGASSNER, Josef, Gottfried , ROCHE, Didier , WATTANASIN, Sompong , WEITZ-SCHMIDT, Gabriele , WELZENBACH, Karl
IPC分类号： C07D401/06 , C07D243/08 , A61K31/4709 , A61K31/551
CPC分类号： C07K5/06139 , A61K38/05 , A61K31/00 , A61K2300/00
摘要： The invention provides novel diazepanes having interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1, -ICAM-2 or -ICAM-3 interactions.
-
公开(公告)号：EP1735295A1
公开(公告)日：2006-12-27
申请号：EP05740303.2
申请日：2005-03-31
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： C07D309/36 , A61K31/366 , A61P29/00
CPC分类号： C07D309/36
摘要： Lactones of Formula (I) which are pharmaceutically active in diseases associated with inflammation.
-
6.发明公开COMBINATION OF A MACROLIDE T-CELL IMMUNOMODULATOR AND A CALCIFEROL FOR THE TREATMENT OF SKIN DISEASES OR OF INFLAMMATORY BOWEL DISEASE 审中-公开大环内酯类T细胞免疫调节剂的WITH A骨化醇FOR皮肤疾病或炎症性肠疾病的治疗组合
公开(公告)号：EP1613330A1
公开(公告)日：2006-01-11
申请号：EP04725344.8
申请日：2004-04-02
申请人： Novartis AG , Novartis Pharma GmbH
发明人： GRASSBERGER, Maximilian , HIRSCH, Stefan , MAYER, Friedrich, Karl , MEINGASSNER, Josef, Gottfried , PAUL, Carle , SEKKAT, Nabila
IPC分类号： A61K31/593 , A61K31/453 , A61P17/00 , A61P1/00
CPC分类号： A61K31/453 , A61K31/593 , A61K2300/00
摘要： Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a calciferol such as calcipotriol or tacalcitol are provided, which are useful in particular in the treatment of dermatological diseases such as atopic dermatitis, acne and psoriasis, or of inflammatory bowel disease (IBD).
-
公开(公告)号：EP1861099A2
公开(公告)日：2007-12-05
申请号：EP06723452.6
申请日：2006-03-15
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/46 , A61K31/436 , A61P29/00
CPC分类号： A61K45/06 , A61K31/436 , A61K31/46 , A61K2300/00
摘要： A combination of a steroid sulfatase inhibitor and an ascomycin, which combination is useful as a pharmaceutical.
-
8.发明公开SYNERGISTIC COMBINATIONS OF A MACROLIDE T-CELL MODULATOR OR IMMUNOSUPPRESSANT AND A RETINOID 审中-公开的协同组合33 EPICHLORO-33脱氧和维甲酸
公开(公告)号：EP1638543A2
公开(公告)日：2006-03-29
申请号：EP04725373.7
申请日：2004-04-02
申请人： Novartis AG
发明人： GRASSBERGER, Maximilian , HIRSCH, Stefan , MAYER, Friedrich, Karl , MEINGASSNER, Josef, Gottfried , PAUL, Carle , SEKKAT, Nabila , STÜTZ, Anton
IPC分类号： A61K31/05
CPC分类号： A61K31/05 , A61K31/07 , A61K31/436 , A61K2300/00
摘要： Additive or synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33epichloro-33-desoxyascomycin and a retinoid, such as etretinate, isotretinoin or tazarotene, optionally with a further pharmaceutically active agent, especially an antibacterial, are provided, which are useful in particular in the treatment of dermatological diseases such as eczema, atopic dermatitis, acne, psoriasis, skin aging, sun damage, post-peel erythema and stretch marks.
-
公开(公告)号：EP1154988B1
公开(公告)日：2004-08-11
申请号：EP00916832.9
申请日：2000-02-14
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BAENTELI, Rolf , BAUER, Wilfried , COTTENS, Sylvain , EHRHARDT, Claus , HOMMEL, Ulrich , KALLEN, Jörg , MEINGASSNER, Josef, Gottfried , NUNINGER, François , WEITZ-SCHMIDT, Gabriele
IPC分类号： C07C235/26 , C07C237/18 , C07C235/30 , C07C237/20 , C07D211/76 , C07D265/24 , C07D401/06 , A61K31/4402 , A61K31/45 , A61K31/4545 , A61K31/535 , A61P9/10 , A61P3/06 , A61P29/00 , A61P37/00
CPC分类号： C07C271/12 , C07C235/26 , C07C235/30 , C07C237/18 , C07C2602/28 , C07D211/76 , C07D265/10
摘要： Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.
-
10.发明授权
公开(公告)号：EP1359905B1
公开(公告)日：2006-07-26
申请号：EP02711840.5
申请日：2002-02-06
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/00 , A61K31/44 , A61K31/495 , A61K31/444 , A61P17/04
CPC分类号： A61K31/444 , A61K31/00 , A61K31/44 , A61K31/495
摘要： The invention provides the use of mGluR5 receptor antagonists for the treatment of pruritic conditions.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.012 秒)
